Dianthus Therapeutics, Inc.

NasdaqCM:DNTH Stock Report

Market Cap: US$661.2m

Dianthus Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Dianthus Therapeutics has a total shareholder equity of $337.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $354.2M and $16.4M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$281.12m
EquityUS$337.90m
Total liabilitiesUS$16.35m
Total assetsUS$354.25m

Recent financial health updates

Recent updates

Dianthus Therapeutics (NASDAQ:DNTH) Is In A Good Position To Deliver On Growth Plans

Jul 03
Dianthus Therapeutics (NASDAQ:DNTH) Is In A Good Position To Deliver On Growth Plans

Financial Position Analysis

Short Term Liabilities: DNTH's short term assets ($287.5M) exceed its short term liabilities ($15.7M).

Long Term Liabilities: DNTH's short term assets ($287.5M) exceed its long term liabilities ($640.0K).


Debt to Equity History and Analysis

Debt Level: DNTH is debt free.

Reducing Debt: DNTH has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DNTH has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: DNTH has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 44.7% each year.


Discover healthy companies